5 completed, 2 terminated, 2 withdrawn. 5 Phase 3, 2 Phase 2, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 2, Terminated 2, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
| Phase 4 | 2 | Completed 2 |
Follow reteplase: new trials by email Literature Review of reteplase trials Research Report on reteplase
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Endovascular Stroke Treatment And Reteplase Protocol Reteplase Injection - Ischemic Stroke | Phase 2 | Withdrawn | Zeenat Qureshi Stroke Institute | 2023-07-01 | 2024-04-09 | |
| A Study of r-PA Treating Patients With Acute Ischemic Stroke（RAISE） Injection of recombinant human tissue plasminogen kinase derivatives, Recombinant human tissue plasminogen activator - Acute Ischemic Stroke | Phase 3 | Completed | Angde Biotech Pharmaceutical Co., Ltd. | 1412 | 2022-03-21 | 2024-03-04 |
| Efficacy and Safety of CUSA-081 in the Restoration of Dysfunctional Central Venous Access Device (CVAD) Functionality CUSA-081 - Restoration of Function to CVADs | Phase 3 | Withdrawn | Chiesi Farmaceutici S.p.A. | 2022-02-28 | 2022-04-15 | |
| Effect of Low-dose Intracoronary Reteplase on Myocardial Infarct Size During Primary Percutaneous Coronary Intervention Normal Saline, Reteplase Injection 9mg, Reteplase Injection 18mg - Acute ST-segment Elevation Myocardial Infarction | Phase 3 | Terminated | Ge Junbo | 36 | 2021-07-01 | 2023-09-14 |
| Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality CUSA-081, Placebo, Alteplase - Catheter Occlusion, Thrombosis | Phase 3 | Terminated | Chiesi Farmaceutici S.p.A. | 462 | 2020-02-12 | 2024-08-23 |
| Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization Reteplase 10 Units (U) plus a second dose of reteplase 10 U, Reteplase 10 U, Urgent Percutaneous Coronary Intervention (PCI) - Heart Disease, Myocardial Infarction | Phase 4 | Completed | The University of Texas Health Science Center, Houston | 390 | 2003-09-01 | 2023-09-06 |
| A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse) abciximab placebo; reteplase placebo, abciximab, abciximab, Abciximab; reteplase; abciximab placebo; abciximab, abciximab; reteplase placebo; abciximab placebo; abciximab - Myocardial Infarction | Phase 3 | Completed | Centocor, Inc. | 2461 | 2002-08-01 | 2014-07-31 |
| ReoPro and Retavase to Restore Brain Blood Flow After Stroke Abciximab (ReoPro) and Reteplase (Retavase) - Cerebrovascular Accident | Phase 2 | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 42 | 2002-03-01 | 2011-09-21 |
| Comparison Between Thrombolysis and Primary Percutaneous Coronary Intervention (PCI) to Treat ST-Segment Elevation Myocardial Infarction reteplase 10+10 U, primary PCI - Acute Myocardial Infarction | Phase 4 | Completed | Sahlgrenska University Hospital | 205 | 2001-11-01 | 2008-12-10 |
Ischemic Stroke (2) · Myocardial Infarction (2) · Bites and Stings (1) · Heart Diseases (1) · ST Elevation Myocardial Infarction (1) · Stroke (1) · Thrombosis (1)
Chiesi Farmaceutici S.p.A. (2) · Angde Biotech Pharmaceutical Co., Ltd. (1) · Centocor, Inc. (1) · Ge Junbo (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · Sahlgrenska University Hospital (1) · The University of Texas Health Science Center, Houston (1) · Zeenat Qureshi Stroke Institute (1)
United States (5) · Argentina (2) · Belgium (2) · Bulgaria (2) · China (2) · Czechia (2) · Germany (2) · Poland (2) · Romania (2) · Spain (2) · Sweden (2) · Austria (1) · Canada (1) · Denmark (1) · France (1)
Ake Ohlsson, M.D. PhD (1) · Johan Herlitz, M.D. PhD (1) · Junbo Ge (1) · Lars Grip, M.D. PhD (1) · Leif Svensson, M.D. PhD (1) · Mikael Aasa, M.D. (1) · Mikael Dellborg, M.D. PhD (1) · Richard W. Smalling, MD, PhD (1) · Yongjun Wang (1)
PMID 15077099, PMID 16569536, PMID 17925603, PMID 18499565, PMID 19850248, PMID 19850249, PMID 20170878, PMID 20691839, PMID 35800360, PMID 38286482, PMID 38884332, PMID 40180551, PMID 42089199
2019 (1)